Institutional Investor Sentiment About Celgene Corp (NASDAQ:CELG) Increased

August 21, 2018 - By Nellie Rakes

Celgene Corporation (NASDAQ:CELG) Logo

Sentiment for Celgene Corp (NASDAQ:CELG)

Celgene Corp (NASDAQ:CELG) institutional sentiment decreased to 0.79 in 2018 Q1. Its down -0.04, from 0.83 in 2017Q4. The ratio dropped, as 469 hedge funds started new and increased stock positions, while 590 sold and reduced their stakes in Celgene Corp. The hedge funds in our partner’s database now hold: 513.18 million shares, down from 561.38 million shares in 2017Q4. Also, the number of hedge funds holding Celgene Corp in their top 10 stock positions decreased from 38 to 28 for a decrease of 10. Sold All: 120 Reduced: 470 Increased: 363 New Position: 106.

Celgene Corporation discovers, develops, and commercializes therapies to treat cancer and inflammatory diseases worldwide. The company has market cap of $63.92 billion. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma, myelodysplastic syndromes , and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis, psoriasis, and ankylosing spondylitis; and ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers. It has a 25.27 P/E ratio. The companyÂ’s products also include VIDAZA, a pyrimidine nucleoside analog for intermediate-2 and high-risk MDS, chronic myelomonocytic leukemia, and acute myeloid leukemia (AML); THALOMID to treat patients with multiple myeloma and erythema nodosum leprosum; and RITALIN and FOCALIN XR products.

The stock increased 0.56% or $0.51 during the last trading session, reaching $90.88. About 3.70M shares traded. Celgene Corporation (NASDAQ:CELG) has declined 32.65% since August 21, 2017 and is downtrending. It has underperformed by 45.22% the S&P500.

Analysts await Celgene Corporation (NASDAQ:CELG) to report earnings on October, 25. They expect $1.99 earnings per share, up 11.80 % or $0.21 from last year’s $1.78 per share. CELG’s profit will be $1.40 billion for 11.42 P/E if the $1.99 EPS becomes a reality. After $1.86 actual earnings per share reported by Celgene Corporation for the previous quarter, Wall Street now forecasts 6.99 % EPS growth.

Birchview Capital Lp holds 41.66% of its portfolio in Celgene Corporation for 709,181 shares. Oaktop Capital Management Ii L.P. owns 2.17 million shares or 40.48% of their US portfolio. Moreover, Edinburgh Partners Ltd has 12.91% invested in the company for 315,906 shares. The New Jersey-based Selkirk Management Llc has invested 12.36% in the stock. Fcg Advisors Llc, a New Jersey-based fund reported 343,318 shares.

Since January 1, 0001, it had 1 buying transaction, and 4 selling transactions for $4.44 million activity.

Celgene Corporation (NASDAQ:CELG) Ratings Coverage

Ratings analysis reveals 69% of Celgene’s analysts are positive. Out of 16 Wall Street analysts rating Celgene, 11 give it “Buy”, 0 “Sell” rating, while 5 recommend “Hold”. The lowest target is $90 while the high is $16300. The stock’s average target of $119.90 is 31.93% above today’s ($90.88) share price. CELG was included in 21 notes of analysts from February 28, 2018. The stock of Celgene Corporation (NASDAQ:CELG) has “Outperform” rating given on Monday, May 7 by RBC Capital Markets. The company was downgraded on Wednesday, May 23 by Argus Research. The stock of Celgene Corporation (NASDAQ:CELG) has “Buy” rating given on Wednesday, February 28 by William Blair. Stifel Nicolaus maintained the shares of CELG in report on Wednesday, February 28 with “Buy” rating. The firm earned “Outperform” rating on Wednesday, February 28 by Credit Suisse. Cantor Fitzgerald maintained it with “Hold” rating and $11200 target in Thursday, May 31 report. The firm has “Equal-Weight” rating given on Friday, July 13 by Morgan Stanley. The rating was upgraded by Standpoint Research to “Buy” on Monday, June 18. The stock of Celgene Corporation (NASDAQ:CELG) earned “Hold” rating by Robert W. Baird on Wednesday, February 28. BMO Capital Markets maintained the stock with “Outperform” rating in Wednesday, February 28 report.

More notable recent Celgene Corporation (NASDAQ:CELG) news were published by: Nasdaq.com which released: “3 Great Stocks for Your IRA” on August 16, 2018, also Fool.com with their article: “Better Buy: Celgene Corporation vs. Bristol-Myers Squibb” published on August 20, 2018, Seekingalpha.com published: “One Year Later: Lessons Learned In CAR-T” on August 14, 2018. More interesting news about Celgene Corporation (NASDAQ:CELG) were released by: Seekingalpha.com and their article: “Is The Bottom In For Celgene?” published on August 14, 2018 as well as Benzinga.com‘s news article titled: “Celgene Q2 Earnings Preview” with publication date: July 25, 2018.

Celgene Corporation (NASDAQ:CELG) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.